Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01008852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Parallel, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.
Study identification
- NCT ID
- NCT01008852
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2009
- Primary completion
- Aug 31, 2011
- Completion
- Jun 30, 2013
- Last update posted
- Dec 2, 2013
2009 – 2013
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Paradise Valley | Arizona | 85253 | — |
| Pfizer Investigational Site | Palm Desert | California | 92260 | — |
| Pfizer Investigational Site | Santa Monica | California | 90404 | — |
| Pfizer Investigational Site | Westlake Village | California | 91361 | — |
| Pfizer Investigational Site | Newark | Delaware | 19713 | — |
| Pfizer Investigational Site | Miami | Florida | 33169 | — |
| Pfizer Investigational Site | Palm Harbor | Florida | 34684 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62704 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01610 | — |
| Pfizer Investigational Site | Grand Rapids | Michigan | 49546 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pfizer Investigational Site | Syracuse | New York | 13210 | — |
| Pfizer Investigational Site | Minot | North Dakota | 58701 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45408 | — |
| Pfizer Investigational Site | Toledo | Ohio | 43606 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74135 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29406 | — |
| Pfizer Investigational Site | Jackson | Tennessee | 38305 | — |
| Pfizer Investigational Site | Spokane | Washington | 99204 | — |
| Pfizer Investigational Site | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01008852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2013 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01008852 live on ClinicalTrials.gov.